Schizophrenia.com
Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study
News
everhopeful
June 15, 2021, 4:21pm
1
5 Likes
RottenApple
June 15, 2021, 4:47pm
2
Sounds promising!
1 Like
Related topics
Topic
Replies
Views
Activity
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
News
4
434
December 13, 2018
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia
News
4
448
April 16, 2020
Drug For Schizophrenia Beginning Phase II Trial
News
14
1338
December 3, 2016
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
News
9
1206
November 23, 2016
Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856
News
3
371
December 13, 2019